Pfizer offers 40m Covid shots to poorer countries at cost
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 24, 2022
TUESDAY, MAY 24, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Pfizer offers 40m Covid shots to poorer countries at cost

Coronavirus chronicle

BSS/AFP
23 January, 2021, 11:50 am
Last modified: 23 January, 2021, 12:00 pm

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot

Pfizer offers 40m Covid shots to poorer countries at cost

Covax — the globally-pooled coronavirus vaccine procurement and equitable distribution effort, aimed at ensuring that lower-income countries get hold of doses too — is hoping to ship its first deliveries in February

BSS/AFP
23 January, 2021, 11:50 am
Last modified: 23 January, 2021, 12:00 pm
Pfizer's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration
Pfizer's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration

Pfizer announced Friday that it will provide up to 40 million of its Covid-19 vaccine doses to poorer countries on a non-profit basis, through the globally-pooled Covax facility.

While dozens of the world's richer countries have begun their vaccination campaigns in a bid to curb the pandemic, coronavirus jabs have been few and far between in the world's poorer nations.

Covax — the globally-pooled coronavirus vaccine procurement and equitable distribution effort, aimed at ensuring that lower-income countries get hold of doses too — is hoping to ship its first deliveries in February.

Covax is co-led by the World Health Organization and Gavi, the Vaccine Alliance. The Pfizer-BioNTech vaccine is the only one so far to have received emergency use approval from the WHO.

Developing countries should have "the same access to vaccines as the rest of the world", Pfizer chairman Albert Bourla told a virtual press conference.

"We will provide the vaccine to Covax for these countries at a not-for-profit basis.

"We are proud to have this opportunity to provide doses that will support Covax's efforts towards vaccinating health care workers at high risk of exposure in developing countries, and other vulnerable populations."

Ready to roll

Set up last year, Covax initially aimed to secure enough Covid-19 vaccines this year for the most vulnerable 20 percent in participating countries.

In Covax, funding is covered through donations for the 92 lower- and lower-middle income economies involved, while for richer countries, buying in operates as a back-up insurance policy.

Gavi chief executive Seth Berkley said nearly 150 million doses of the AstraZeneca-Oxford vaccine were ready to ship through Covax — pending emergency use approval from the WHO, which is on course to happen in mid- February.

He said Covax should be able to deliver those doses in the first quarter of 2021.

Covax still needs to finalise a supply agreement for the Pfizer-BioNTech vaccine.

Berkley said Covax could procure 2.3 billion vaccine doses this year, which, he said, would equate to close to 1.8 billion doses for the poorest 92 countries — enough to vaccinate about 27 percent of the population, an upgrade on the initial target.

'Science will win'

WHO director-general Tedros Adhanom Ghebreyesus said vaccines were offering the hope of ending the pandemic and repairing the global economy.

However, "to do that, we need every member state, every partner, and every vaccine producer on board".

Speaking more broadly than Covax, Pfizer's Bourla said he felt confident that Pfizer-BioNTech could produce two billion Covid-19 vaccine doses by the end of 2021.

"Science will win, and will win for everyone," he said.

Asked about how many vaccine doses all manufacturers might be able to produce this year, Gavi's Berkley said: "I think we're talking about numbers in the range of six to seven billion doses".

Doctors Without Borders said the 40 million doses offered to Covax by Pfizer were a drop in the ocean and a lamentable "pittance" compared to the direct deals it has struck with high-income countries.

"We call on pharmaceutical corporations like Pfizer and its peers to supply the Covax facility with the volumes it needs at an at-cost price," the medical charity's Dana Gill said in a statement.

"If the world is going to emerge from this pandemic, we absolutely must distribute these vaccines equitably, not based upon who can pay the most."

Top News

COVAX / Pfizer coronavirus vaccine / Pfizer Covid-19 Vaccine / Pfizer-BioNTech vaccine / Pfizer-BioNTech coronavirus vaccine / Pfizer Inc / Pfizer vaccine / Pfizer/BioNTech Covid-19 vaccine / covid-19 vaccine / Coronavirus Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Corporates go cashless…tax cut on cards
    Corporates go cashless…tax cut on cards
  • Rising revenue collection a false dawn, economists say
    Rising revenue collection a false dawn, economists say
  • Why we must resist geoeconomic fragmentation—and how
    Why we must resist geoeconomic fragmentation—and how

MOST VIEWED

  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing urges millions to keep working from home amid Covid outbreak menace
  • Picture: PTI
    Saudi Arabia bans travel to India, 15 other countries over Covid outbreaks
  • A person in personal protective equipment (PPE) walks a dog at a resident community, as the second stage of a two-stage lockdown has been launched to curb the spread of the coronavirus disease (Covid-19) in Shanghai, China April 3, 2022. REUTERS/Aly Song
    Shanghai reopens some public transport, still on high Covid alert
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Dynamic zero-Covid approach: China's choice to safeguard lives, underpin growth
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot

Features

Musk is denying the sexual harassment allegation that surfaced this week. Photo: Bloomberg

Elon Musk’s crazily banal week 

10h | Panorama
Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

14h | Brands
Keep your phone by your side with this armband

Keep your phone by your side with this armband

11h | Brands
Are Focallure gel masks worth the hype?

Are Focallure gel masks worth the hype?

12h | Brands

More Videos from TBS

Why are Duranta TV shows popular?

Why are Duranta TV shows popular?

6h | Videos
Donbas is hell, says Zelenskiy

Donbas is hell, says Zelenskiy

7h | Videos
Threat of Monkeypox on the horizon

Threat of Monkeypox on the horizon

8h | Videos
Mosque of Mughal period in Gazipur

Mosque of Mughal period in Gazipur

8h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab